Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 21 U.S.C. §355 (n)(4)

Karl Schwartz	Karl	Sc	hwa	rtz
---------------	------	----	-----	-----

Committee:

Oncologic Drugs Advisory Committee

Meeting Date:

September 6, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 20-287, Fragmin (dalteparin sodium injection), sponsored by Pfizer, Inc., for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)) to reduce the recurrence of VTE in patients with cancer, I am eligible to receive a waiver under 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude			
Stock	Sector Mutual Fund	Valued at less than \$5,001			
Stock	Sector Mutual Fund	Valued between \$5,001 to \$25,000			
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.					
/s/		8/3/06			
Signature		Date			